Concepts (255)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Multiple Sclerosis | 12 | 2024 | 44 | 7.720 |
Why?
|
| Dementia | 11 | 2021 | 50 | 5.370 |
Why?
|
| Urinary Bladder, Overactive | 8 | 2021 | 13 | 5.040 |
Why?
|
| United States | 48 | 2024 | 495 | 5.030 |
Why?
|
| Aged | 49 | 2024 | 703 | 4.940 |
Why?
|
| Depression | 13 | 2020 | 125 | 4.830 |
Why?
|
| Humans | 89 | 2024 | 4936 | 4.680 |
Why?
|
| Retrospective Studies | 40 | 2024 | 341 | 4.580 |
Why?
|
| Cholinesterase Inhibitors | 8 | 2024 | 20 | 4.360 |
Why?
|
| Cholinergic Antagonists | 9 | 2024 | 20 | 4.230 |
Why?
|
| Medicare | 20 | 2024 | 78 | 3.990 |
Why?
|
| Antipsychotic Agents | 10 | 2024 | 48 | 3.930 |
Why?
|
| Alzheimer Disease | 6 | 2024 | 62 | 3.830 |
Why?
|
| Female | 55 | 2024 | 2523 | 3.760 |
Why?
|
| Male | 52 | 2024 | 2491 | 3.580 |
Why?
|
| Nursing Homes | 15 | 2021 | 31 | 3.490 |
Why?
|
| Muscarinic Antagonists | 8 | 2024 | 18 | 2.810 |
Why?
|
| Practice Patterns, Physicians' | 12 | 2024 | 47 | 2.580 |
Why?
|
| Pneumonia | 4 | 2022 | 20 | 2.420 |
Why?
|
| Adolescent | 28 | 2024 | 758 | 2.300 |
Why?
|
| Arthritis, Rheumatoid | 3 | 2023 | 12 | 2.270 |
Why?
|
| Cohort Studies | 14 | 2024 | 115 | 2.050 |
Why?
|
| Aged, 80 and over | 19 | 2024 | 262 | 2.010 |
Why?
|
| Middle Aged | 17 | 2024 | 967 | 2.000 |
Why?
|
| Patient Readmission | 3 | 2022 | 8 | 1.920 |
Why?
|
| Adult | 17 | 2024 | 1567 | 1.920 |
Why?
|
| Fingolimod Hydrochloride | 4 | 2024 | 9 | 1.880 |
Why?
|
| Heart Failure | 6 | 2023 | 30 | 1.810 |
Why?
|
| Analgesics, Opioid | 7 | 2024 | 73 | 1.770 |
Why?
|
| Health Expenditures | 4 | 2024 | 18 | 1.720 |
Why?
|
| Recurrence | 2 | 2024 | 23 | 1.680 |
Why?
|
| Parkinson Disease | 3 | 2020 | 39 | 1.640 |
Why?
|
| Machine Learning | 3 | 2023 | 35 | 1.620 |
Why?
|
| Cognitive Dysfunction | 3 | 2020 | 55 | 1.620 |
Why?
|
| Antirheumatic Agents | 2 | 2023 | 7 | 1.590 |
Why?
|
| Logistic Models | 11 | 2024 | 64 | 1.500 |
Why?
|
| Paroxetine | 3 | 2017 | 8 | 1.490 |
Why?
|
| Prescription Drugs | 3 | 2023 | 15 | 1.430 |
Why?
|
| Ambulatory Care | 2 | 2021 | 9 | 1.370 |
Why?
|
| Homes for the Aged | 5 | 2017 | 11 | 1.330 |
Why?
|
| Drug Prescriptions | 4 | 2023 | 25 | 1.260 |
Why?
|
| Dimethyl Fumarate | 3 | 2024 | 6 | 1.210 |
Why?
|
| Case-Control Studies | 10 | 2024 | 81 | 1.160 |
Why?
|
| Asthma | 2 | 2019 | 8 | 1.150 |
Why?
|
| Risk Factors | 10 | 2024 | 159 | 1.130 |
Why?
|
| Young Adult | 9 | 2024 | 787 | 1.110 |
Why?
|
| Antidepressive Agents, Second-Generation | 3 | 2021 | 5 | 1.110 |
Why?
|
| Cross-Sectional Studies | 9 | 2023 | 269 | 1.070 |
Why?
|
| Hip Fractures | 2 | 2018 | 3 | 1.040 |
Why?
|
| Treatment Outcome | 7 | 2023 | 177 | 1.030 |
Why?
|
| Crotonates | 2 | 2024 | 4 | 1.030 |
Why?
|
| Medication Adherence | 3 | 2024 | 69 | 0.980 |
Why?
|
| Immunosuppressive Agents | 5 | 2024 | 19 | 0.960 |
Why?
|
| Cardiovascular Diseases | 2 | 2023 | 43 | 0.930 |
Why?
|
| Interrupted Time Series Analysis | 2 | 2024 | 12 | 0.910 |
Why?
|
| Hypnotics and Sedatives | 2 | 2024 | 10 | 0.910 |
Why?
|
| Skin Neoplasms | 1 | 2024 | 16 | 0.870 |
Why?
|
| Delirium | 1 | 2024 | 7 | 0.860 |
Why?
|
| Immunologic Factors | 4 | 2024 | 17 | 0.860 |
Why?
|
| Melanoma | 1 | 2024 | 28 | 0.850 |
Why?
|
| Hydroxybutyrates | 1 | 2024 | 2 | 0.830 |
Why?
|
| Toluidines | 1 | 2024 | 2 | 0.830 |
Why?
|
| Nitriles | 1 | 2024 | 11 | 0.830 |
Why?
|
| Neoplasms | 2 | 2023 | 90 | 0.820 |
Why?
|
| Child | 19 | 2024 | 627 | 0.810 |
Why?
|
| Biological Products | 1 | 2023 | 9 | 0.790 |
Why?
|
| Lymphoma, Non-Hodgkin | 1 | 2023 | 3 | 0.780 |
Why?
|
| Health Care Surveys | 5 | 2021 | 14 | 0.780 |
Why?
|
| Office Visits | 2 | 2020 | 3 | 0.740 |
Why?
|
| Quality of Life | 2 | 2022 | 87 | 0.730 |
Why?
|
| Drug-Related Side Effects and Adverse Reactions | 2 | 2022 | 7 | 0.720 |
Why?
|
| Longitudinal Studies | 5 | 2024 | 137 | 0.710 |
Why?
|
| Accidental Falls | 2 | 2024 | 9 | 0.700 |
Why?
|
| Comorbidity | 5 | 2020 | 47 | 0.690 |
Why?
|
| Ambulatory Care Facilities | 1 | 2021 | 4 | 0.690 |
Why?
|
| Potentially Inappropriate Medication List | 1 | 2021 | 1 | 0.690 |
Why?
|
| Anti-Arrhythmia Agents | 1 | 2021 | 1 | 0.690 |
Why?
|
| Cyclooxygenase Inhibitors | 1 | 2021 | 1 | 0.690 |
Why?
|
| Patient Discharge | 2 | 2022 | 18 | 0.680 |
Why?
|
| Hypoglycemic Agents | 1 | 2021 | 14 | 0.680 |
Why?
|
| Incidence | 6 | 2019 | 30 | 0.670 |
Why?
|
| Withholding Treatment | 2 | 2020 | 10 | 0.670 |
Why?
|
| Mandelic Acids | 1 | 2020 | 1 | 0.650 |
Why?
|
| Pyrrolidines | 1 | 2020 | 1 | 0.650 |
Why?
|
| Urological Agents | 1 | 2020 | 1 | 0.650 |
Why?
|
| Benzofurans | 1 | 2020 | 6 | 0.640 |
Why?
|
| Cost of Illness | 1 | 2020 | 4 | 0.640 |
Why?
|
| Activities of Daily Living | 2 | 2022 | 46 | 0.630 |
Why?
|
| Cost-Benefit Analysis | 1 | 2020 | 18 | 0.630 |
Why?
|
| Drug Utilization | 2 | 2017 | 5 | 0.630 |
Why?
|
| Proton Pump Inhibitors | 2 | 2019 | 4 | 0.620 |
Why?
|
| Attention Deficit Disorder with Hyperactivity | 2 | 2017 | 25 | 0.620 |
Why?
|
| Severity of Illness Index | 2 | 2019 | 51 | 0.610 |
Why?
|
| Mental Disorders | 4 | 2024 | 48 | 0.600 |
Why?
|
| Psychotropic Drugs | 5 | 2019 | 13 | 0.590 |
Why?
|
| Documentation | 1 | 2019 | 4 | 0.580 |
Why?
|
| Adrenal Cortex Hormones | 1 | 2019 | 5 | 0.580 |
Why?
|
| Pediatrics | 1 | 2019 | 6 | 0.580 |
Why?
|
| Anti-Asthmatic Agents | 1 | 2019 | 3 | 0.580 |
Why?
|
| Myasthenia Gravis | 1 | 2018 | 1 | 0.570 |
Why?
|
| Osteoporotic Fractures | 1 | 2018 | 1 | 0.550 |
Why?
|
| Linear Models | 5 | 2023 | 58 | 0.550 |
Why?
|
| Risk | 5 | 2018 | 34 | 0.540 |
Why?
|
| Patient Discharge Summaries | 1 | 2016 | 1 | 0.500 |
Why?
|
| Decision Support Techniques | 1 | 2016 | 7 | 0.500 |
Why?
|
| Medication Therapy Management | 1 | 2016 | 6 | 0.500 |
Why?
|
| Fractures, Bone | 1 | 2016 | 7 | 0.490 |
Why?
|
| Substance-Related Disorders | 1 | 2017 | 47 | 0.480 |
Why?
|
| Medicaid | 6 | 2023 | 29 | 0.480 |
Why?
|
| Outpatients | 4 | 2023 | 11 | 0.480 |
Why?
|
| Disabled Persons | 1 | 2016 | 11 | 0.480 |
Why?
|
| Odds Ratio | 4 | 2021 | 17 | 0.480 |
Why?
|
| Community-Acquired Infections | 1 | 2016 | 2 | 0.480 |
Why?
|
| Health Services Accessibility | 3 | 2021 | 26 | 0.460 |
Why?
|
| Polypharmacy | 3 | 2022 | 8 | 0.460 |
Why?
|
| Cognition | 2 | 2023 | 140 | 0.450 |
Why?
|
| Prevalence | 3 | 2021 | 66 | 0.410 |
Why?
|
| Methotrexate | 2 | 2023 | 5 | 0.400 |
Why?
|
| Drug Therapy, Combination | 2 | 2023 | 26 | 0.400 |
Why?
|
| Health Care Costs | 2 | 2024 | 12 | 0.380 |
Why?
|
| Administration, Oral | 2 | 2024 | 33 | 0.370 |
Why?
|
| Dose-Response Relationship, Drug | 2 | 2024 | 52 | 0.370 |
Why?
|
| Age Factors | 2 | 2024 | 65 | 0.370 |
Why?
|
| Propensity Score | 3 | 2017 | 11 | 0.360 |
Why?
|
| Rivastigmine | 2 | 2022 | 6 | 0.360 |
Why?
|
| Galantamine | 2 | 2022 | 6 | 0.360 |
Why?
|
| Phenylcarbamates | 2 | 2022 | 5 | 0.360 |
Why?
|
| Indans | 2 | 2022 | 7 | 0.350 |
Why?
|
| Proportional Hazards Models | 4 | 2020 | 28 | 0.350 |
Why?
|
| Risk Assessment | 3 | 2016 | 44 | 0.350 |
Why?
|
| Piperidines | 2 | 2022 | 15 | 0.350 |
Why?
|
| Acetylcholinesterase | 2 | 2021 | 4 | 0.340 |
Why?
|
| Healthcare Disparities | 3 | 2019 | 17 | 0.330 |
Why?
|
| Algorithms | 2 | 2023 | 241 | 0.320 |
Why?
|
| Angiotensin Receptor Antagonists | 2 | 2023 | 17 | 0.320 |
Why?
|
| Depressive Disorder, Major | 2 | 2019 | 17 | 0.290 |
Why?
|
| Diabetes Mellitus, Type 2 | 2 | 2022 | 39 | 0.280 |
Why?
|
| Bipolar Disorder | 2 | 2019 | 10 | 0.280 |
Why?
|
| Drug Monitoring | 2 | 2024 | 10 | 0.270 |
Why?
|
| Body Mass Index | 4 | 2023 | 98 | 0.260 |
Why?
|
| SEER Program | 2 | 2024 | 7 | 0.250 |
Why?
|
| Emergency Service, Hospital | 2 | 2024 | 12 | 0.250 |
Why?
|
| Hospitalization | 3 | 2024 | 38 | 0.250 |
Why?
|
| Prescriptions | 2 | 2024 | 19 | 0.240 |
Why?
|
| Prognosis | 2 | 2023 | 60 | 0.230 |
Why?
|
| Urinary Incontinence | 1 | 2024 | 2 | 0.220 |
Why?
|
| Autoimmune Diseases | 1 | 2024 | 6 | 0.220 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 1 | 2024 | 9 | 0.220 |
Why?
|
| Sex Factors | 1 | 2024 | 76 | 0.210 |
Why?
|
| Lung Neoplasms | 1 | 2024 | 25 | 0.210 |
Why?
|
| Qualitative Research | 1 | 2024 | 38 | 0.210 |
Why?
|
| Multiple Sclerosis, Relapsing-Remitting | 1 | 2024 | 8 | 0.210 |
Why?
|
| Analgesics, Non-Narcotic | 1 | 2024 | 6 | 0.200 |
Why?
|
| Acute Pain | 1 | 2023 | 4 | 0.200 |
Why?
|
| Glucocorticoids | 1 | 2023 | 3 | 0.200 |
Why?
|
| Ventricular Dysfunction, Left | 1 | 2023 | 4 | 0.200 |
Why?
|
| Chronic Disease | 2 | 2020 | 25 | 0.190 |
Why?
|
| Aftercare | 1 | 2022 | 6 | 0.190 |
Why?
|
| Hospitals | 1 | 2022 | 10 | 0.190 |
Why?
|
| Lennox Gastaut Syndrome | 1 | 2022 | 1 | 0.190 |
Why?
|
| Epilepsies, Myoclonic | 1 | 2022 | 2 | 0.190 |
Why?
|
| Cannabidiol | 1 | 2022 | 2 | 0.190 |
Why?
|
| Drug Resistant Epilepsy | 1 | 2022 | 4 | 0.190 |
Why?
|
| Epilepsy | 1 | 2022 | 11 | 0.190 |
Why?
|
| Metformin | 1 | 2022 | 9 | 0.190 |
Why?
|
| Glatiramer Acetate | 1 | 2022 | 2 | 0.180 |
Why?
|
| Child Psychiatry | 2 | 2024 | 6 | 0.180 |
Why?
|
| Managed Care Programs | 2 | 2019 | 7 | 0.180 |
Why?
|
| Weight Gain | 2 | 2019 | 27 | 0.180 |
Why?
|
| Sitagliptin Phosphate | 1 | 2021 | 1 | 0.170 |
Why?
|
| Diltiazem | 1 | 2021 | 1 | 0.170 |
Why?
|
| Sotalol | 1 | 2021 | 1 | 0.170 |
Why?
|
| Dipeptidyl-Peptidase IV Inhibitors | 1 | 2021 | 1 | 0.170 |
Why?
|
| Citalopram | 1 | 2021 | 2 | 0.170 |
Why?
|
| Thiazolidinediones | 1 | 2021 | 4 | 0.170 |
Why?
|
| Calcium Channel Blockers | 1 | 2021 | 4 | 0.170 |
Why?
|
| Tolterodine Tartrate | 1 | 2021 | 2 | 0.170 |
Why?
|
| Anti-Inflammatory Agents, Non-Steroidal | 1 | 2021 | 10 | 0.170 |
Why?
|
| Area Under Curve | 1 | 2021 | 16 | 0.170 |
Why?
|
| Injections | 1 | 2021 | 9 | 0.170 |
Why?
|
| Disease Progression | 1 | 2021 | 59 | 0.170 |
Why?
|
| Angiotensin-Converting Enzyme Inhibitors | 2 | 2023 | 16 | 0.170 |
Why?
|
| Breast Neoplasms | 1 | 2022 | 96 | 0.160 |
Why?
|
| Surveys and Questionnaires | 1 | 2022 | 258 | 0.160 |
Why?
|
| Research Design | 1 | 2020 | 29 | 0.160 |
Why?
|
| Models, Economic | 1 | 2020 | 3 | 0.160 |
Why?
|
| Electronic Health Records | 1 | 2020 | 16 | 0.160 |
Why?
|
| Schools, Pharmacy | 1 | 2019 | 24 | 0.150 |
Why?
|
| Blood Glucose | 3 | 2023 | 29 | 0.150 |
Why?
|
| Time Factors | 2 | 2017 | 163 | 0.150 |
Why?
|
| Quality of Health Care | 1 | 2019 | 5 | 0.150 |
Why?
|
| Geography | 1 | 2019 | 6 | 0.150 |
Why?
|
| Sinusitis | 1 | 2019 | 1 | 0.150 |
Why?
|
| Administration, Inhalation | 1 | 2019 | 5 | 0.150 |
Why?
|
| Gastroesophageal Reflux | 1 | 2019 | 2 | 0.150 |
Why?
|
| Protein-Tyrosine Kinases | 1 | 2019 | 12 | 0.140 |
Why?
|
| Physicians | 1 | 2019 | 17 | 0.140 |
Why?
|
| Minority Groups | 1 | 2019 | 35 | 0.140 |
Why?
|
| Socioeconomic Factors | 1 | 2019 | 38 | 0.140 |
Why?
|
| Residence Characteristics | 1 | 2019 | 23 | 0.140 |
Why?
|
| Protein Kinase Inhibitors | 1 | 2019 | 25 | 0.140 |
Why?
|
| Liver Diseases | 1 | 2018 | 2 | 0.140 |
Why?
|
| Mental Health Services | 1 | 2018 | 13 | 0.140 |
Why?
|
| Education, Pharmacy | 1 | 2019 | 73 | 0.130 |
Why?
|
| Texas | 4 | 2019 | 190 | 0.130 |
Why?
|
| Outpatient Clinics, Hospital | 1 | 2017 | 2 | 0.130 |
Why?
|
| Clostridium Infections | 1 | 2018 | 56 | 0.130 |
Why?
|
| Adrenergic Uptake Inhibitors | 1 | 2017 | 3 | 0.130 |
Why?
|
| Atomoxetine Hydrochloride | 1 | 2017 | 4 | 0.130 |
Why?
|
| Antidepressive Agents | 1 | 2017 | 14 | 0.130 |
Why?
|
| Physicians, Primary Care | 1 | 2017 | 7 | 0.130 |
Why?
|
| Central Nervous System Stimulants | 1 | 2017 | 8 | 0.130 |
Why?
|
| Tertiary Care Centers | 1 | 2016 | 5 | 0.130 |
Why?
|
| Follow-Up Studies | 1 | 2017 | 83 | 0.120 |
Why?
|
| Academic Medical Centers | 1 | 2016 | 5 | 0.120 |
Why?
|
| Multivariate Analysis | 1 | 2016 | 15 | 0.120 |
Why?
|
| Databases, Factual | 1 | 2016 | 26 | 0.120 |
Why?
|
| Evidence-Based Medicine | 1 | 2016 | 5 | 0.120 |
Why?
|
| Infant | 3 | 2023 | 78 | 0.120 |
Why?
|
| Medicare Part D | 1 | 2015 | 7 | 0.120 |
Why?
|
| Medicare Part C | 1 | 2016 | 32 | 0.110 |
Why?
|
| Child, Preschool | 3 | 2023 | 180 | 0.110 |
Why?
|
| Hypertension | 1 | 2016 | 58 | 0.110 |
Why?
|
| Analgesics | 2 | 2024 | 6 | 0.110 |
Why?
|
| Animals | 1 | 2020 | 1711 | 0.100 |
Why?
|
| Stroke Volume | 2 | 2023 | 12 | 0.100 |
Why?
|
| Adrenergic beta-Antagonists | 2 | 2023 | 10 | 0.100 |
Why?
|
| Pain | 2 | 2024 | 41 | 0.100 |
Why?
|
| Primary Health Care | 2 | 2021 | 46 | 0.080 |
Why?
|
| Infant, Newborn | 2 | 2019 | 48 | 0.070 |
Why?
|
| Interviews as Topic | 1 | 2024 | 24 | 0.050 |
Why?
|
| Pain Management | 1 | 2024 | 14 | 0.050 |
Why?
|
| Ambulatory Surgical Procedures | 1 | 2024 | 2 | 0.050 |
Why?
|
| Chronic Pain | 1 | 2024 | 22 | 0.050 |
Why?
|
| Isosorbide Dinitrate | 1 | 2023 | 1 | 0.050 |
Why?
|
| Cholesterol | 1 | 2023 | 17 | 0.050 |
Why?
|
| Opioid-Related Disorders | 1 | 2024 | 34 | 0.050 |
Why?
|
| Anticonvulsants | 1 | 2022 | 3 | 0.050 |
Why?
|
| Seizures | 1 | 2022 | 9 | 0.050 |
Why?
|
| Postmenopause | 1 | 2022 | 7 | 0.050 |
Why?
|
| Receptor, ErbB-2 | 1 | 2022 | 17 | 0.050 |
Why?
|
| Leadership | 1 | 2019 | 15 | 0.040 |
Why?
|
| Pharmaceutical Services | 1 | 2019 | 18 | 0.040 |
Why?
|
| Pharmacy | 1 | 2019 | 16 | 0.040 |
Why?
|
| Peptic Ulcer | 1 | 2019 | 2 | 0.040 |
Why?
|
| Deprescriptions | 1 | 2019 | 3 | 0.040 |
Why?
|
| Drug Interactions | 1 | 2019 | 8 | 0.040 |
Why?
|
| Survival Rate | 1 | 2019 | 14 | 0.040 |
Why?
|
| Information Storage and Retrieval | 1 | 2019 | 14 | 0.040 |
Why?
|
| Body Weight | 1 | 2019 | 58 | 0.040 |
Why?
|
| Health Personnel | 1 | 2018 | 20 | 0.030 |
Why?
|
| Students, Pharmacy | 1 | 2019 | 73 | 0.030 |
Why?
|
| Predictive Value of Tests | 1 | 2016 | 30 | 0.030 |
Why?
|
| Models, Statistical | 1 | 2015 | 62 | 0.030 |
Why?
|
| Reproducibility of Results | 1 | 2016 | 318 | 0.030 |
Why?
|